Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xerostomia and becomes dose-limiting for 225 Ac-PSMA-617.…
Introduction: PSMA radio ligand therapy (PRLT) is a promising treatment for mCRPC patients. However, an intense uptake to the salivary glands (SG) can be observed with moderate xerostomia. For Ac-225- PSMA xerostomia became even dose-limiting. Objective of this study was a systematic investigation of…